Press Releases Press Releases Year None20192018 September 11, 2019 Stoke Therapeutics Added to Russell 2000 and 3000 Indexes August 20, 2019 Stoke Therapeutics Enrolls First Patient in an Observational Study of Children and Adolescents Living with Dravet Syndrome August 14, 2019 Stoke Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update August 6, 2019 Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome August 1, 2019 Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference June 21, 2019 Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares June 18, 2019 Stoke Therapeutics Announces Pricing of Initial Public Offering June 14, 2019 Stoke Therapeutics Appoints Jennifer Burstein to its Board of Directors March 19, 2019 Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer March 7, 2019 Stoke Therapeutics to Present on First Disease-Modifying Therapies for Genetic Epilepsies at Cowen and Company Annual Health Care Conference Pagination Current page 1 Page 2 Next page next › Last page last » Toolkit Print Page Email Alerts Contact IR FAQ
Press Releases Year None20192018 September 11, 2019 Stoke Therapeutics Added to Russell 2000 and 3000 Indexes August 20, 2019 Stoke Therapeutics Enrolls First Patient in an Observational Study of Children and Adolescents Living with Dravet Syndrome August 14, 2019 Stoke Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update August 6, 2019 Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome August 1, 2019 Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference June 21, 2019 Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares June 18, 2019 Stoke Therapeutics Announces Pricing of Initial Public Offering June 14, 2019 Stoke Therapeutics Appoints Jennifer Burstein to its Board of Directors March 19, 2019 Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer March 7, 2019 Stoke Therapeutics to Present on First Disease-Modifying Therapies for Genetic Epilepsies at Cowen and Company Annual Health Care Conference Pagination Current page 1 Page 2 Next page next › Last page last »
August 20, 2019 Stoke Therapeutics Enrolls First Patient in an Observational Study of Children and Adolescents Living with Dravet Syndrome
August 14, 2019 Stoke Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
August 6, 2019 Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome
June 21, 2019 Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 19, 2019 Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer
March 7, 2019 Stoke Therapeutics to Present on First Disease-Modifying Therapies for Genetic Epilepsies at Cowen and Company Annual Health Care Conference